Angewandte Chemie (International ed. in English) · 2024
Multifunctional, Fluorene-Based Modulator of Cholinergic and GABAergic Neurotransmission as a Novel Drug Candidate for Palliative Treatment of Alzheimer's Disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Panek Dawid, Pasieka Anna, Jończyk Jakub, Gawlińska Milena, Zaręba Paula, Siwek Agata, Wolak Małgorzata, Mordyl Barbara, Głuch-Lutwin Monika, Latacz Gniewomir, Brazzolotto Xavier, Chantegreil Fabien, Nachon Florian, Zdarova Karasova Jana, Pejchal Jaroslav, Mzik Martin, Sestak Vit, Prchal Lukas, Odvarkova Jitka, Soukup Ondrej, Korabecny Jan, Sorf Ales, Hamsikova Marie, Zemanova Lucie, Muckova Lubica, Vánova Nela, Dryja Pola, Sałat Kinga, Höfner Georg, Wanner Klaus, Więckowska Anna, Malawska Barbara
Аннотация
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by memory loss and behavioral and psychological symptoms of dementia (BPSD). Given that cholinergic neurons are predominantly affected in AD, current treatments primarily aim to enhance cholinergic neurotransmission. However, imbalances in other neurotransmitters, such as γ-aminobutyric acid (GABA), also contribute to AD symptomatology. In the presented research, using a combination of crystallography and computational methods we developed compound 6 as a dual modulator of GABAergic and cholinergic neurotransmission systems. Compound 6 demonstrated inhibition of BuChE (IC50=0.21 μM) and GABA transporter 1 (IC50=10.96 μM) and 3 (IC50=7.76 μM), along with a favorable drug-likeness profile. Subsequent in vivo studies revealed the effectiveness of 6 in enhancing memory retention and alleviating anxiety and depression symptoms in animal models, while also proving safe and bioavailable for oral administration. The innovative multi-target-directed ligand 6 offers a new approach to treating cognitive deficits and BPSD in AD.